Results 131 to 140 of about 25,876,318 (284)

Intratumoral Hypoxia Triggers Mitochondrial BHLHE40 ROS Sensing Pathway to Promote Radioresistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Hypoxia triggers a dual mechanism for BHLHE40 upregulation: reactive oxygen species (ROS)‐dependent post‐translational modification and hypoxia‐inducible factor (HIF)‐dependent transcriptional activation. Under hypoxic conditions, mitochondrial BHLHE40 accumulates and senses ROS via cysteine thiol oxidation and disulfide‐linked homodimer formation ...
Jia Liu, Ziliang Nie, Xi Chen, Guangyu Ji, Yajing Zhang, Zhiqun Zhao, Yuhong Zhang, Xinlong Du, Zhenzhen Zhou, Jiayi Li, Yaozong Yang, Fengqi Sun, Zhibo Yan, Haiquan Lu   +13 more
wiley   +1 more source

UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression

Advanced Science, EarlyView.
UFMylation restrains aerobic glycolysis and colorectal cancer progression by modifying the glycolytic enzyme ENO1. Pharmacological enhancement of the UFL1–ENO1 interaction by the FDA‐approved antibiotic torezolid promotes ENO1 UFMylation, suppresses tumor metabolism, and sensitizes colorectal cancer to chemotherapy, revealing an actionable metabolic ...
Xiuqing Ma, Rui Wan, Yueyuan Zhong, Ziyang Cui, Xuan Zhang, Xiaoqiang He, Rong Wang, Lei Huang, Wan‐Yang Sun, Rong‐Rong He, Yang Zhou, Jianshuang Li, Li Shen, Shao‐Hua Wang, Tongzheng Liu   +14 more
wiley   +1 more source

Sodium–glucose co-transporter 2 inhibitors in heart failure

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
Giuseppe M C Rosano, Cristiana Vitale, Gianluigi Savarese   +2 more
openaire   +2 more sources

Sodium glucose transporter 2 inhibitors for heart failure

World Journal of Cardiology
Heart failure (HF) is a leading cause of cardiovascular morbidity and mortality, affecting over 64 million individuals worldwide. Despite advances in guideline-directed medical therapy, patients with HF continue to experience poor outcomes, highlighting the need for novel therapeutic approaches.
Daisuke Usuda, Daiki Furukawa, Rikako Imaizumi, Rikuo Ono, Yuki Kaneoka, Eri Nakajima, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura, Manabu Sugita   +26 more
openaire   +1 more source

Brief Report: Use and Side Effects of Sodium-Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications. [PDF]

J Acquir Immune Defic Syndr, 2023
Sise ME, Katz-Agranov N, Strohbehn IA, Harden D, Moreno D, Durbin C, Toribio M, Neilan TG, Zanni MV.   +8 more
europepmc   +1 more source

Tumor‐Derived Exosomal circAP2B1 Induces M2 Macrophage Polarization by Enhancing Mitochondrial Homeostasis to Promote Esophageal Squamous Cell Carcinoma Progression

Advanced Science, EarlyView.
ESCC‐derived exosomal circAP2B1 promotes tumor progression by reprogramming mitochondrial metabolism via the ESRRA/KPNA1/MFN2 axis to induce M2 polarization of macrophages. ABSTRACT Esophageal squamous cell carcinoma (ESCC) remodels the immunosuppressive tumor microenvironment via exosome‐mediated intercellular communication.
Yiru Wang, Gang Feng, Youyu Wang, Ruihao Liang, Haixia Pan, Kai Lei   +5 more
wiley   +1 more source

Sodium-glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia. [PDF]

ESC Heart Fail, 2023
Tang WJ, Yu M.
europepmc   +1 more source

Unveiling the Taxonomic Diversity and Unprecedented Biosynthetic Treasure of the Phylum Myxococcota

Advanced Science, EarlyView.
Natural products remain vital sources of therapeutics, and the phylum Myxococcota constitutes an especially rich reservoir for them. Based on decades of microbiological efforts, we present 154 new Myxococcota genomes and revise taxonomy quadrupling the number of families and genera.
Amay Ajaykumar Agrawal, Ronald Garcia, Guangyi Chen, Chantal D. Bader, Peter Sullivan, Alexander Popoff, Daniel Krug, Maja Hunter, Sebastian Walesch, Emilia Oueis, Christine Frank, Haowen Zhao, Joachim J. Hug, Sebastian Keller, Pascal Hirsch, Azat Tagirdzhanov, Tatiana Malygina, Mary Victory E. Gutierrez, Alexey Gurevich, Judith Boldt, Boyke Bunk, Jörg Overmann, Ulrich Nübel, Andreas Keller, Olga V. Kalinina, Rolf Müller   +25 more
wiley   +1 more source

The peri-operative implications of sodium-glucose co-transporter 2 inhibitors: a narrative review

Introduction: Sodium-glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss.
Nestor, Claire C, Irwin, Michael G, Clancy, Cillian, Stewart, Paul A   +3 more
core   +1 more source

METTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer

Advanced Science, EarlyView.
GC cells enhance glutamine accumulation by upregulating SLC1A5 expression. This upregulation not only boosts GC cell proliferation, but also outcompetes CD8+ T cells for glutamine and suppresses their antitumor immunity. Mechanistically, METTL7A deficiency in GC induces SLC1A5 overexpression via an m6A‐dependent pathway and N‐glycosylation ...
Mingjun Sun, Shuwei Dang, Dazhi Zhou, Lixian Ding, Xun Sun, Wei Suo, Jirui Niu, Qingzhu Yang, Zhicheng Zhang, Yanyan Sun, Jinxing Li, Zhongsheng Chen, Tao Ban, Yingji Wang, Tianzhu Li, Ming Liu, Guodong Li   +16 more
wiley   +1 more source